Skip to main content
European Commission logo print header

The first Integrated m-Health solution for anaphylaxis management.

Obiettivo

Adan Medical Innovation is a private company focused on the medical devices and the m-health solutions markets. We have patented an m-Health technology for anaphylaxis management, which consists on a smart case for an epinephrine auto-injector linked via Bluetooth to a medical mobile app. Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. The only adequate treatment is an immediate intramuscular epinephrine injection by using an auto-injector. However, patient self-management of auto-injectors has several problems: a) Need to check periodically drug condition, b) low adherence because patients forget carrying the auto-injector, c) difficulties to administer intramuscular epinephrine.
Adanmi has developed the first integrated solution to solve all these issues: a) The smart auto-injector case monitors epinephrine condition; b) The smartphone alerts distance from auto-injector in case the subject forgets it, c) during anaphylaxis it initiates an automated emergency protocol alerting contacts with exact GPS location and providing administration video-instructions.

Invito a presentare proposte

H2020-SMEInst-2016-2017

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-1-2016-2017

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

ADAN MEDICAL INNOVATION SL
Contribution nette de l'UE
€ 50 000,00
Indirizzo
ANGLI 31 4 1
08017 BARCELONA
Spagna

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Este Cataluña Barcelona
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00